Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Market Cap | 90.316 Billion | Shares Outstanding | 257.552 Million | Avg 30-day Volume | 906.264 Thousand |
P/E Ratio | 27.2333 | Dividend Yield | 0.0 | EPS | 3.55 |
Price to Revenue | 9.641 | Debt to Equity | 0.0 | EBITDA | 4.11 Billion |
Price to Book Value | 5.9235 | Operating Margin | 41.7212 | Enterprise Value | 79.044 Billion |
Current Ratio | 4.139 | EPS Growth | 0.048 | Quick Ratio | 3.816 |
1 Yr BETA | 0.5341 | 52-week High/Low | 367.0 / 276.57 | Profit Margin | 35.4014 |
Operating Cash Flow Growth | 1.2443 | Free Cash Flow to Firm (FCFF) TTM | 2.902 Billion | Free Cash Flow to Equity (FCFE) TTM | 2.905 Billion |
Altman Z-Score | 13.5579 | ||||
Earnings Report | 2023-10-26 |
Please sign in first
none
39.9 Thousand total shares from 8 transactions
10 Thousand total shares from 1 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
BOZIC CARMEN EVP AND CMO |
|
51,905 | 2023-09-19 | 6 |
ATKINSON EDWARD MORROW III EVP, CHIEF TECHNICAL OPS. OFF. |
|
13,879 | 2023-08-29 | 1 |
TATSIS OURANIA EVP, CHIEF REG. & QUALITY OFF. |
|
48,637 | 2023-08-23 | 7 |
|
6,536 | 2023-08-10 | 2 | |
SACHDEV AMIT EVP, CHIEF PATIENT OFFICER |
|
66,261 | 2023-08-10 | 5 |
ALTSHULER DAVID EVP, GLOBAL RESEARCH AND CSO |
|
32,038 | 2023-08-09 | 9 |
|
4,386 | 2023-08-09 | 3 | |
KEWALRAMANI RESHMA CEO & PRESIDENT |
|
118,906 | 2023-07-17 | 7 |
|
40,000 | 2023-07-14 | 7 | |
|
0 | 2023-07-14 | 5 | |
ARBUCKLE STUART A EVP, COO |
|
56,696 | 2023-06-15 | 9 |
AMBROSE KRISTEN SVP & CHIEF ACCOUNTING OFFICER |
|
6,838 | 2023-05-30 | 4 |
LEIDEN JEFFREY M EXECUTIVE CHAIRMAN |
|
72,339 | 2023-05-05 | 5 |
SANNA BASTIANO EVP, CELL & GENETIC THERAPIES |
|
32,038 | 2023-05-05 | 14 |
|
5,318 | 2023-05-01 | 2 | |
|
0 | 2023-05-01 | 1 | |
|
6,474 | 2023-05-01 | 1 | |
|
0 | 2023-05-01 | 5 | |
|
2,726 | 2023-05-01 | 3 | |
WAGNER CHARLES F JR EVP & CHIEF FINANCIAL OFFICER |
|
49,611 | 2023-03-24 | 7 |
BILLER JONATHAN EVP AND CHIEF LEGAL OFFICER |
|
11,587 | 2023-02-01 | 1 |
LIU JOY SVP, GENERAL COUNSEL |
|
9,605 | 2022-08-15 | 0 |
SILVA PAUL M SVP & CHIEF ACCOUNTING OFFICER |
|
22,719 | 2021-02-26 | 0 |
PARINI MICHAEL EVP, CHIEF ADM, LEG & BD OFF |
|
30,837 | 2021-02-24 | 0 |
|
No longer subject to file | 2020-06-01 | 0 | |
|
0 | 2019-06-01 | 0 | |
GRANEY THOMAS CHIEF FINANCIAL OFFICER |
|
12,430 | 2018-10-01 | 0 |
SMITH IAN F EVP, COO |
|
52,005 | 2018-06-29 | 0 |
|
No longer subject to file | 2018-04-01 | 0 | |
|
No longer subject to file | 2017-06-08 | 0 | |
|
0 | 2015-06-01 | 0 | |
CONNOLLY THOMAS SVP, HUMAN RESOURCES |
|
34,525 | 2014-12-12 | 0 |
HORTON KENNETH L EVP & CHIEF LEGAL OFFICER |
|
72,419 | 2014-11-17 | 0 |
PACE MEGAN E SVP, CORP. COMMUNICATIONS |
|
43,350 | 2014-11-17 | 0 |
MUELLER PETER EVP, GLOBAL R&D, CSO |
|
169,088 | 2014-06-16 | 0 |
STAMOULIS CHRISTIANA SVP, CORP STRATEGY & BUS DEVLP |
|
0 | 2013-07-30 | 0 |
KELLY LISA SVP, HUMAN RESOURCES |
|
27,347 | 2013-02-05 | 0 |
|
0 | 2012-06-01 | 0 | |
WYSENSKI NANCY EVP, CHIEF COMMERCIAL OFFICER |
|
32,232 | 2012-05-14 | 0 |
|
6,500 | 2012-03-09 | 0 | |
HOWTON DAVID T SVP & CHIEF LEGAL OFFICER |
|
19,703 | 2012-02-02 | 0 |
BOGER KENNETH S SVP & CHIEF LEGAL OFFICER |
|
292,187 | 2011-09-13 | 0 |
|
12,000 | 2011-03-17 | 0 | |
|
0 | 2010-06-01 | 0 | |
|
0 | 2010-06-01 | 0 | |
|
0 | 2010-03-15 | 0 | |
GRAVES KURT EVP, CHIEF COMMERCIAL OFFICER |
|
60,485 | 2009-10-19 | 0 |
GARRISON RICHARD C SVP AND CATALYST |
|
38,782 | 2009-05-18 | 0 |
LEWIS-HALL FREDA C EVP, MEDICINES DEVELOPMENT |
|
53,334 | 2009-03-19 | 0 |
|
0 | 2009-01-29 | 0 | |
ALAM JOHN J EVP, MED. DEV. GROUP & CMO |
|
141,932 | 2008-10-01 | 0 |
POWER JOHANNA MESSINA VP & CONTROLLER |
|
0 | 2008-07-24 | 0 |
|
20,000 | 2007-06-01 | 0 | |
HARTMANN VICTOR A EVP, STRATEGIC & CORP. DEVLP. |
|
198,305 | 2007-05-03 | 0 |
BRUM LYNNE H VP, STRATEGIC COMMUNICATIONS |
|
330,935 | 2006-05-08 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-09-21 16:15:36 -0400 | 2023-09-19 | S | 5,651 | $351.00 | d | 51,905 | direct | yes | 0.3262 | 0.3262 | 2 | 0.0 | 1 | |||
2023-09-07 16:29:38 -0400 | 2023-09-05 | S | 5,651 | $352.66 | d | 57,556 | direct | yes | 1.2156 | 1.7053 | 1.8569 | 5 | 0.0 | 1 | ||
2023-08-25 16:14:50 -0400 | 2023-08-23 | S | 2,500 | $355.00 | d | 48,637 | direct | yes | -0.0967 | -0.9499 | 0.0 | 1 | -0.9499 | 6 | ||
2023-08-14 16:05:14 -0400 | 2023-08-10 | S | 10,031 | $350.00 | d | 58,814 | direct | yes | -1.8211 | 0.1773 | 0.2745 | 5 | -1.8211 | 2 | ||
2023-08-14 16:08:52 -0400 | 2023-08-10 | S | 5,750 | $345.79 | d | 51,137 | direct | yes | -1.8211 | 0.1773 | 0.2745 | 5 | -1.8211 | 2 | ||
2023-08-14 16:09:17 -0400 | 2023-08-10 | M | 10,000 | $127.54 | a | 16,536 | direct | yes | -1.8211 | 0.1773 | 0.2745 | 5 | -1.8211 | 2 | ||
2023-08-14 16:09:17 -0400 | 2023-08-10 | S | 10,000 | $350.00 | d | 6,536 | direct | yes | -1.8211 | 0.1773 | 0.2745 | 5 | -1.8211 | 2 | ||
2023-08-14 16:09:17 -0400 | 2023-08-10 | M | 10,000 | d | 10,000 | direct | yes | |||||||||
2023-08-11 16:05:13 -0400 | 2023-08-09 | S | 63 | $345.51 | d | 32,038 | direct | yes | 0.1174 | 0.3921 | 0.3921 | 6 | -1.7059 | 3 | ||
2023-08-11 16:05:08 -0400 | 2023-08-09 | S | 242 | $345.51 | d | 4,386 | direct | yes | 0.1174 | 0.3921 | 0.3921 | 6 | -1.7059 | 3 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-26 13:45:03 UTC | 5.07 | 0.25 | 8000000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-26 13:15:03 UTC | 5.07 | 0.25 | 8000000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-26 12:45:05 UTC | 5.07 | 0.25 | 7900000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 22:15:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 21:45:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 21:15:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 20:45:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 20:15:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 19:45:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 19:15:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 18:45:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 18:15:03 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 17:45:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 17:15:03 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 16:45:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 16:15:03 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 15:45:03 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 15:15:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 14:45:04 UTC | 5.07 | 0.25 | 8100000 |
VERTEX PHARMACEUTICALS INC VRTX | 2023-09-25 14:15:04 UTC | 5.07 | 0.25 | 8100000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
FundVantage Trust- Gotham Absolute 500 Core Fund | VRTX | -44.0 shares, $-10469.8 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Enhanced 500 Plus Fund | VRTX | -29.0 shares, $-10205.39 | 2023-06-30 | N-PORT |